<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Many diabetic patients suffer from a <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> that cannot be explained by poor coronary perfusion </plain></SENT>
<SENT sid="1" pm="."><plain>Reactive oxygen species (ROS) have been proposed to contribute to this <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Consistent with this we found evidence for induction of the <z:chebi fb="11" ids="22586">antioxidant</z:chebi> genes for catalase in diabetic OVE26 hearts </plain></SENT>
<SENT sid="3" pm="."><plain>To determine whether increased <z:chebi fb="11" ids="22586">antioxidant</z:chebi> protection could reduce diabetic <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo>, we assessed cardiac <z:mp ids='MP_0000002'>morphology</z:mp> and contractility, Ca(2+) handling, malondialdehyde (<z:chebi fb="14" ids="32506">MDA</z:chebi>)-modified proteins, and ROS levels in individual cardiomyocytes isolated from control hearts, OVE26 diabetic hearts, and diabetic hearts overexpressing the <z:chebi fb="11" ids="22586">antioxidant</z:chebi> protein catalase </plain></SENT>
<SENT sid="4" pm="."><plain>Diabetic hearts showed damaged mitochondria and myofibrils, reduced myocyte contractility, slowed intracellular Ca(2+) decay, and increased <z:chebi fb="14" ids="32506">MDA</z:chebi>-modified proteins compared with control myocytes </plain></SENT>
<SENT sid="5" pm="."><plain>Overexpressing catalase preserved <z:mpath ids='MPATH_458'>normal</z:mpath> cardiac <z:mp ids='MP_0000002'>morphology</z:mp>, prevented the contractile defects, and reduced <z:chebi fb="14" ids="32506">MDA</z:chebi> protein modification but did not reverse the slowed Ca(2+) decay induced by <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>Additionally, high <z:chebi fb="105" ids="17234">glucose</z:chebi> promoted significantly increased generation of ROS in diabetic cardiomyocytes </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0011010'>Chronic</z:hpo> overexpression of catalase or <z:hpo ids='HP_0011009'>acute</z:hpo> in vitro treatment with <z:chebi fb="0" ids="28201">rotenone</z:chebi>, an inhibitor of <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> complex I, or thenoyltrifluoroacetone, an inhibitor of <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> complex II, eliminated excess ROS production in diabetic cardiomyocytes </plain></SENT>
<SENT sid="8" pm="."><plain>The structural damage to diabetic mitochondria and the efficacy of <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> inhibitors in reducing ROS suggest that mitochondria are a source of oxidative damage in diabetic cardiomyocytes </plain></SENT>
<SENT sid="9" pm="."><plain>We also found that catalase overexpression protected cardiomyocyte contractility in the agouti model of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="10" pm="."><plain>These data show that both type 1 and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> induce damage at the level of individual myocytes, and that this damage occurs through mechanisms utilizing ROS </plain></SENT>
</text></document>